Skip to main contentSkip to navigationSkip to search

Article from Phase II study in prostate cancer now published in the March issue of Journal of Nuclear Medicine and highlighted as best clinical investigation article

February 26, 2021


As previously communicated in December 2020, results from the investigator-initiated phase II study performed by researchers at Rigshospitalet were available in 2020. Now, these results are published in the March 2021 issue of the Journal of Nuclear Medicine, which is the most recognized scientific journal in the field of nuclear medicine (highest impact factor). Furthermore, the article (available here) ( has been selected as Featured Clinical Investigation Article of the March issue.

The phase II study

The phase II study aimed to evaluate the correlation between uptake on uPAR-PET with 68Ga-NOTA-AE105 (uTRACE®) and Gleason Score in prostate cancer patients undergoing prostate biopsy. SUV*) measurements from uPAR PET in primary tumors as delineated by mpMRI showed a significant correlation with Gleason score, and tumor SUVmax was able to discriminate between low-risk and intermediate-risk Gleason score profiles with high diagnostic accuracy. Consequently, uPAR PET/MRI could be a promising method for non-invasive prostate cancer evaluation, which may in the future potentially reduce the need for repeated biopsies, e.g. in active surveillance.

About the Journal of Nuclear Medicine

The Journal of Nuclear Medicine is the official publication of the Society for Nuclear Medicine and Molecular Imaging and the highest-ranked journal within nuclear medicine based on the number of citations (impact factor).

We are excited not only that the study from Rigshospitalet has been published in the March issue of Journal of Nuclear Medicine but in particular that it has been selected as the best clinical investigation article. This underscores the quality and impact of the study. Furthermore, and as previously communicated, the study has demonstrated a first proof-of-concept for the idea of using uPAR-PET as a non-invasive measure of cancer aggressiveness in prostate cancer. We believe this supports the potential of using imaging for saving some of the biopsies currently taken. Curasight will take this information into consideration when planning the optimal design of a future Curasight sponsored phase III study in prostate cancer.” says CEO Ulrich Krasilnikoff.

*) Standardized uptake value (SUV) is a measure of PET tracer concentration. SUVmax is a measure of the maximal value of SUV within a certain region, e.g. within the volume of a tumor. Gleason score is a grading system of prostate cancer aggressiveness based on pathological evaluation of tissue from the tumor.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60



Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.